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The karyotypes of a large proportion of carcinomas are highly
abnormal, with many translocated or otherwise rearranged chro-
mosomes and numerical changes (Dutrillaux, 1995; Heim, 1996).
This is particularly so for breast carcinomas: in about two-thirds
of cases, more than 20% of the chromosomes show structural
rearrangements (Dutrillaux et al, 1991). These rearrangements
must play some part in the genetic changes that drive carcinoma
development, yet we know rather little about them. Classical chro-
mosome banding could not reliably analyse such grossly abnormal
karyotypes (Veldman et al, 1997; Macville et al, 1999; Adeyinka
et al, 2000). FISH (fluorescence in situ hybridization) techniques,
however, now make it possible to identify chromosomes unam-
biguously and hence obtain accurate karyotypes (Schrock et al,
1996; Speicher et al, 1996; Morris et al, 1997).
We report the application of 24-colour chromosome painting,
together with comparative genomic hybridization (CGH), to 20
breast cell lines, 19 from breast cancers and one (HB4a) from
SV40-immortalized normal mammary luminal epithelial cells. In
24-colour chromosome painting, each of the 24 human chromo-
somes is hybridized simultaneously to chromosome paint, but
each chromosome is labelled with a different combination of
fluorochromes (Schrock et al, 1996; Speicher et al, 1996). CGH
complements the karyotyping by showing large-scale gains and
losses of chromosomal material, providing an indication of which
regions of chromosomes are over- or under-represented in the
karyotypes (Macville et al, 1999).
MATERIALS AND METHODS
Cell culture and metaphase spreads
Cell lines obtained from originators and cultured accordingly
were: CAL51 (Gioanni et al, 1990); HB4a (Stamps et al, 1994);
MaTu/Ham, MT-1, MT-3 (Hambly et al, 1997) – MaTu/Ham was
rederived from a xenograft of the original MaTu of Widmaier et al
(1974); SUM-159 (Forozan et al, 1999); VP229 and VP267
(McCallum and Lowther, 1996). Other lines were cultured in
50:50 DMEM/Ham’s F12 nutrient mixture, 10% (v/v) FCS,
insulin (10 mg ml–1), antibiotics and, for HB4a, hydrocortisone
(5 mg ml–1). Lines PMC42 (Whitehead et al, 1983), SK-BR-3 and
SK-BR-7 (Fogh and Trempe, 1975; SK-BR-7 was derived by the
same authors) were obtained via Dr MJ O’Hare. ATCC lines were
obtained via ECACC (European Cell and Animal Culture
Collection) (MDA-MB-361, T-47D and ZR-75–1) or Dr O’Hare
(MCF-7, MDA-MB-134, MDA-MB-157, MDA-MB-175, MDA-
MB-435, ZR-75–30). Second samples of MaTu and MT-1 were
obtained for authentication from Dr I Fichtner, MDC, Berlin, the
laboratory where xenografts that gave rise to MaTu/Ham and
MT-1 were derived (Naundorf et al, 1993).
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Fluorescence in situ hybridization1
24-colour chromosome painting was performed by the ‘spectral
karyotyping’ (SKY) technique, essentially as described (Schrock
et al, 1996; Roberts et al, 1999). Briefly, metaphases were
hybridized with chromosome paints for all the chromosomes
simultaneously, each chromosome being labelled directly or indi-
rectly with a distinct combination of up to five fluorochromes:
fluorescein, Spectrum Orange, Texas Red, Cy5 and Cy5.5. These
chromosome paints were either from Applied Spectral Imaging
(Migdal HaEmek, Israel) or as described (Roberts et al, 1999).
Metaphases were imaged on a fluorescence microscope to show
all five fluorochromes simultaneously, and the fluorescence
analysed using a spectrometer and CCD camera (Spectracube,
Applied Spectral Imaging). DNA was counterstained and imaged
separately with DAPI (4,6-diamino-2-phenylindole). The supplied
software analyses the spectrum of each pixel of the image, 
determines which dyes are present and hence which chromosome.
Each pixel of the image is then presented false-coloured in a ‘clas-
sification colour’ to show which chromosome spectrum best
matches the spectrum recorded, as in Figure 1.
Ten metaphases were analysed by 24-colour fluorescence,
except for MCF-7, and in addition chromosome copy numbers and
translocated fragments were verified in a number of additional
metaphases analysed by conventional 2- or 3-colour chromosome
painting using separate fluorescent dyes for each chromosome
paint. Representative karyotypes (Table 1) were assembled as
follows: all rearranged chromosomes present in at least two
metaphases were listed, and the number of copies of each chromo-
some given is the mode, except where noted. The metaphases
illustrated in Figure 1 show all the abnormal chromosomes present
in two or more metaphases. They comprised one typical
metaphase, with additional chromosomes from other metaphases
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scaled where necessary. As a result the number of copies of chro-
mosomes shown in this metaphase is not necessarily the same as
the (modal) number given in Table 1.
Individual chromosome paints for conventional chromosome
painting, and centromeric repeat probes (prelabelled, from Oncor),
were labelled and hybridized as described (Courtay-Cahen et al,
2000). For 3-colour analysis FITC, Spectrum Orange (or Cy3) and
Cy5 were used.
Comparative genomic hybridization (CGH) was done essen-
tially as described (Kallioniemi et al, 1994; Courjal and Theillet,
Figure 1 24-colour karyotypes. These two plates show the full representative karyotypes of the more complex lines (except the three lines analysed previously
by reverse painting, MDA-MB-361, T-47D and ZR-75-1, which are illustrated in more detail in Figures 6–8 of Morris et al (1997)); the deviations from diploidy for
the lines with near-diploid karyotypes (except CAL51 and MT-3); and examples of analysis of individual chromosomes showing how the 24-colour analysis is
completed by conventional chromosome painting. In the karyotype images, the chromosomes are shown in classification colours (see text). Some of these
classifications are incorrect in detail, as illustrated in P and Q, and the correct identifications are listed in Table 1. A MaTu/Ham; B MCF-7; C MT-1;
D MDA-MB-435; E MDA-MB-157; F PMC42; G SK-BR-3; H VP229; I VP267; J ZR-75-30; K HB4a. L to O deviations from diploid for near-diploid lines – all
copies, both translocated and apparently normal, of the chromosomes affected by rearrangement are shown: L MDA-MB-175; M MDA-MB-134; N SUM-159;
O SK-BR-7. In M the 8;11 translocation has an hsr that is a coamplification of material from chromosomes 8 and 11 (Bautista & Theillet, 1998) much of which is
misclassified as chromosome 13. P, Q examples of the completion of analysis of aberrant chromosomes by conventional chromosome painting. In both, the first
image is an RGB representation of the fluorescence of the chromosome; the second image is the classification of this fluorescence by the software, and the
subsequent images are copies of this chromosome from a conventional chromosome painting experiment. P 1;X translocation on MCF-7, showing artefactual
identification of strips of chromosomes 3 and 6 in the region where the fluorescence of the 1 (stained with dyes BCD) and X (dyes AE) fragments overlap to
create spectra expected for 3 (dyes ACDE) and 6 (dyes BCDE); and two-colour hybridization with 1 (green) and X (red) paints. Chromosome 3 and 6 paints did
not hybridize (not shown). Q der (?)t(20;14;(8;17)n;14) of ZR-75-30. A region of this chromosome is made up of interleaved small pieces of chromosomes
8 (dye D) and 17 (dye C), whose blended fluorescence was classified as chromosome 4 (dyes CD) and, where close to chromosome 14 material (dye B),
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Table 1 Karyotypes of the 20 breast cell lines
CAL51 (ISCN notation)a 46(45–46), XX
MaTu 69(62–70). 1´3, 2´2, del(2)(q?), der(3)t(1;3)(q22;?), der(12?)ins(3;12), der(3)t(3;10), der(3)t(3;20), 4´2, 5´3, i(5)(p)´3, 6´2, i(6)(p), 7´4, 8´4, 9´3, 10´2,
11´1, der(11)dup(11)(?), der(11)t(11;15)(q21;?), 12´3, 13´2, 14´2, 15´2, der(15)t(3;15), 16´3, 17´3, 18´2, 19´1, dup(19), der(19)t(13;19)(q12;?), 20´3, 21´3,
22´1, der(22)t(8;22)(q23–24.2;?), X´3 cp[10]
MCF-7 65 (61–72).1´1, der(1)t(X;1), 2´2, der(2)t(2;3)(q36;?), 3´2, del(3)(p?), der(3)t(3;6), 4´3, 5´3, der(5)t(5;13)(p12?;q22), 6´1, der(6)t(6;7), der(6)t(3;6), 7´1,
der(7)t(1;19;7;6), der(7)t(7;19;7), 8´1, der(?)t(16;11;8;11;3), der(8)t(8;15), der(8?)t(8;12), der(8)t(8;16), 9´2, der(?)t(6;20;9;3), der(9)t(8;9), 10´2,
der(10)t(7;10)(?;q22), 11´2, der(?)t(11;1;17;19;17), 12´3, der(19)t(12;19), del(13)(q?), der(13)t(13;15;11;16), der(13)t(13;14), der(13)t(13;16), 14´2,
der(?)t(7;14), 15´2, der(16)t(15;16), 16´2, 17´1, der(17)t(3;17), 18´2, der(18)t(18;21), 19´1, der(19)t(7;19), 20´1, der(?)t(17;1;19;17;20),
der(20)t(3;20;1;20;1;20), der(20)t(20;1;21), 21´3, der(22)t(7;22), der(22)t(16;22), X´2 cp[6]
MDA-MB-134 44 (37–47) and 66(60–77).1´2, 2´2, 3´2, 4´2, 5´2, 6´2, 7´2, 8´1, der(?)t(8;11)ins(11;8)n´2, 9´2, 10´2, 11´1, 12´2, 13´1, 14´2, 15´1,
der(?)t(15;17), 16´1, 17´1, 18´1, der(18)t(16;18), 19´2, 20´2, 21´2, 22´2, X´2 cp[8]/idem´2, –1, –5, +16´2, –19, –X, –der(?)t(8;11)ins(8;11)n, –der(18)t(16;18),
–der(?)t(15;17) [7]
MDA-MB-157 62 (41–68) and 116(101–120).1´1, der(1)t(1;13)(?;q21), der(1)t(5;16;1)´2, der(1)t(1;20)´2, 2´1, del(2)(p?), der(2)t(2;8), 3´2, der(3)t(3;4), 4´2,
5´2, 6´2, der(16)t(6;16), 7´3, 8´1, del(8)(p?), i(8)(q?)´2, der(?)t(8;18), 9´1, der(9)t(X;9), 10´2, 11´2, 12´1, der(12)t(12;19), 13´1, i(13)(q), der(14)t(9;14)´2,
der(?)t(14;22;17)´2, der(5)t(5;15)´2, 16´1, 17´2, 18´2, 19´2, der(19)t(10;19)´2, 20´2, der(20)ins(20;13)´2, der(21)t(16;21)´2, der(21)t(X;21), X´3 cp[5]/idem,
– der(1)t(1;13), + del(1)(q31)´2 [5]/idem´2, +del(8)(p?), –i(13)(q)´2, –19, +der(19)t(10;19), –der(20)ins(20;13)´2, +21´2, –der(21)t(16;21), –X [6].
MDA-MB-175 48 (43–48).1´1, der(1?)t(1;2), 2´1, der(2)t(2;17), 3´2, 4´1, der(4?)t(4;15), 5´2, 6´2, 7´1, dic(1;7)t(1;7)´2, 8´2, 9´2, 10´2, 11´1, der(8?)t(8;11)´2,
12´2, 13´2, 14´2, 15´1, 16´2, 17´1, 18´1, 19´2, 20´3, 21´3, 22´3, X´2 cp[10]
MDA-MB-361 51(43–57).1´1, del(1)(p31.1), 2´2, del(2)(p?), 3´2, der(3)t(3;7;13), 4´2, der(4)t(1;4), 5´1, i(5)(p)?, der(?)t(5;20), 6´2, der(6?)t(6;12;15;22), 7´2,
8´1, der(8)t(8;17;8), der(8)t(8;17;15), 9´1, der(?)t(9;11), 10´2, der(10)t(1;10), der(11)t(2;11), der(?)t(11;16), 12´3, 13´1, der(?)t(13;21), 14´1, der(X)t(14;18;X),
der(14)t(14;16), der(?)t(X;15), 16´1, der(16)t(X;16), der(16)t(12;16), der(?)t(16;20), der(16)t(16;17), der(?)t(7;17), der(17)t(16;17), der(17)t(9;17), 18´2,
der(?)t(18;20), 19´2, del(20)(p?), 21´1, 22´2, X´1 cp[10]
MDA-MB-435 57(44–62).1´1, der(1)t(1;7), der(1)t(1;10), 2´2, del(2)(p?), 3´2, del(3)(p?), der(3)t(3;19), 4´2, 5´2, del(5)(q?), 6´2, der(6)t(6;7), 7´2, 8´1,
del(8)(p), der(8)t(8;15), 9´2, 10´2, del(10), der(10)t(10;18), 11´2, der(11)t(8;11), 12´2, 13´1, der(13)t(11;13), 14´1, der(14)t(1;14), der(?)t(14;16), 15´2, 16´2,
17´2, 18´1, der(?)t(18;19), 19´1, der(?)t(6;19), 20´1, del(20), der(?)t(20;21)´2, 21´1, 22´2, der(22?)t(6;22), X´2 cp[10]
MT-1 103(90–103).1´4, del(1), 2´1, der(2)t(X;2;7), der(2)t(X;2), der(2)t(2;18), 3´2, der(3)t(1;3), der(12)ins(3;12), der(3)t(3;20), der(?)t(3;1;6), 4´3, 5´1,
dup(5)(p?), i(5)(p), der(5)t(3;5), der(5)t(5;10)´2, der(5)t(5;15), 6´1, del(6)´2, der(6)t(6;22)´2, der(6)t(6,21)b, 7´2, i(7)(q), del(7)(q?), der(7)t(7;15), 8´4,
der(8)t(9;8;17), der(8)t(6;8;17), 9´3, der(9)t(9;21), 10´3, der(10)t(1;10)´2, 11´3, der(2)t(15;11;2), 12´3, 13´3, del(13), der(19)t(13;19)´2, der(19)t(13;19), 14´3,
der(14)t(1;14), 15´3, 16´4, del(16)´2, 17´3, der(17)t(5;17), 18´3, del(18), 19´3, 20´5, 21´1, der(21)t(6;21)´2, 22´1, der(22)t(8;22), X´3 cp[10]
MT-3 (ISCN notation)a 46(36–47), X, +7, i(13)(q), –X [10]
PMC42 57(52–67).1´2, del(1)(q?), 2´1, del(2)(p?), 3´1, del(3)(p?), der(3)t(3;11), 4´2, 5´4, 6´2, 7´3, der(7)t(7;10), 8´2, del(8)(q?), 9´2, 10´2, 11´1, del(11)(p?),
der(11)t(9;11)´2, 12´3, 13´2, 14´2, der(14)t(10;14), 15´3, 16´2, der(16)t(16;17), 17´2, 18´2, der(?)t(8;18), 19´1, der(19)t(2;19)´2, der(19)t(15;19), 20´4, 21´2,
22´2, X´1, der(X)t(X;2) cp[10]
SK-BR-3 79(68–79). 1´1, i(1)(q), der(1?)t(1;4), der(1)t(1;5), der(1)t(1;10), der(1)t(1;5), del(1)?, 2´2, der(?)t(2;6;4), der(2)t(2;6)´2, 3´2, del(3), 4´1, der(?)t(4;14),
5´2, der(?)t(5;19;4;8), del(5), 6´2, 7´7, 8´1, der(8?)t(13;3;8;3;8;13)´2, der(?)t(8;14), der(8)t(8;21), der(?)t(X;8)´2, der(?)t(20;3;8;17;19;8;3;13), 9´2, 10´1,
del(10)´2, der(10?)t(6;4;6;10), 11´4, 12´2, der(12)t(3;12)(?;q23)´2, 13´1, der(13)t(13;20), der(14)t(5;14), der(?)t(9;14), 15´2, del(15), der(15)t(15;17), 16´2,
der(16)t(7;16)´2, 17´1, der(?)t(20;19;8;17), 18´2, del(18), 19´1, der(?)t(19;22), 20´3, 21´3, 22´2, X´2 cp[10]
SK-BR-7 43(38–44).1´1, der(1)t(1;4), der(?)t(1;19), 2´2, 3´2, der(15?)t(4;15), der(4)t(4;9), 5´2, 6´2, 7´2, 8´2, 9´1, 10´2, 11´2, 12´2, 13´2, 14´1,
der(9)t(9;14), 15´1, 16´2, 17´2, 18´2, 19´1, 20´2, 21´2, 22´1, X´2 cp[10]
SUM-159 47(46–59). 1´2, 2´2, 3´2, 4´2, 5´2, del(5)(q11.2), 6´2, 7´2, 8´2, 9´1, der(9)t(X;9), 10´2, 11´2, 12´2, 13´1, der(13)t(8;13), der(?)t(14;13;8), 14´1,
15´2, 16´2, 17´1, der(17)t(7;17)(p22;?), 18´2, 19´2, 20´2, 21´2, 22´2, X´1, der(X)t(X;9) cp[10]
T-47D 62(44–66).1´2, der(16)t(1;16), 2´2, 3´2, del(3)(p?), der(?)ins(3;5), 4´2, der(?)t(4;5), 5´2, 6´2, 7´2, der(7)t(7;15)´2, 8´2, der(8)t(8;14)´2, der(9)t(9;17)´2,
der(10)t(10;20), der(10)t(10;20), der(10)t(3;10)´2, del(10)´2, 11´2, del(11)(p?)´2, 12´1, der(12)t(12;16), der(12)t(12;13), del(12)(p?), 13´2, 14´2, 15´1,
der(?)ins(9;15)´2, 16´2, 17´2, 18´2, del(18), 19´2, 20´2, 21´2, 22´2, X´1, der(X)t(X;6) cp[10]
VP229 62(56–66). der(1)t(1;14), der(X)t(X;1), der(?)t(1;9;10?;22), der(1)t(1;3), 2´1, der(?)t(14;20;2)*, der(2)t(22;2;3), der(2)t(2;7), der(2)t(2;14)*,
der(2)t(12;4;2;3;2)´2, der(3)t(2;3), der(3)t(3;22), der(3)t(10;12;10;12;3), der(3)t(11;3;10;1?)*, 4´1, der(4)t(19;4;X;12), 5´1, del(5)(q?), der(5)t(5;6), der(5)t(5;14),
6´2, der(6)t(6;15), 7´2, del(7)(q?)´2, 8´2, der(8)t(8;X), der(8)t(19;1;8), 9´1, der(9)t(4;9), 10´2, 11´1, der(?)t(20;3;11)*, der(X)t(X;11), 12´1, der(?)t(12;?)´2,
13´1, der(13)t(20;13), i(14)(q?), der(?)t(14;17?), der(14)t(11;14), 15´2, 16´2, 17´1, der(?)t(16;17), der(17)t(17;10;3;10;3;10), 18´2, 19´2, 20´2, der(20)t(20;3),
21´1, der(21?)t(21;7), der(?)t(20;22) cp[10]
VP267 59(50–59) der(1)t(1;9?;10;1), der(1)t(1;12;10;12), der(1)t(1;14), der(?)t(1;9;10?;22), der(2)t(2;3), der(2)t(2;4), der(2)t(16;2;22), der(3)t(2;3), der(3)t(2;3),
4´1, der(4)t(2;3;2;4;12), del(5)(q?), der(5)t(5;1;4;3;6), der(5)t(2;5), 6´1, der(6), 7´2, del(7)´2, 8´1, der(8)t(8;14)*, der(8?)t(8;3;4;10;3;4?;10;4?;10?)?,
der(8)t(8;19)´2, 9´1, der(9)t(9;13), 10´2, del(10), 11´2, 12´2, der(12)t(6;12), 13´1, 14´1, del(14), der(14)t(11;14), der(14)t(14;22), 15´1, i(15),
der(15)t(15;4;11;2), 16´2, der(16)dup(16)?, 17´2, 18´2, 19´2, 20´3, der(20)t(20;?;12;X), 21´1, der(21)t(21;22), 22´1, der(22)t(21;22), X´1 cp[10]
ZR-75–1 72(51–75). 1´2, der(1)t(1;12)(?;q14), del(1)(p?)hsr(1)?, 2´3, 3´3, 4´3, 5´3, 6´1, del(6)(q?)´2, 7´3, der(22)t(7;22)´3, 8´3, der(8)t(8;11)(p12;?), 9´3,
10´3, der(11)t(11;17)´2, 12´3, der(?)t(12;16), der(?)t(1;12), 13´2, 14´2, der(14)t(13;14), 15´2, der(15)t(10;15), der(15)t(1;15), 16´1, i(16)(q), i(16)(p), 17´2,
der(?)t(6;17), 18´4, 19´2, del(19)(p?), 20´2, i(20)(q), 21´2, 22´2, der(22)t(15;22)*, X´3 cp[10]
ZR-75–30 79(76–80).1´2, der(1)t(1;21)(p34.1;?)´2, 2´3, 3´4, 4´4, 5´2, der(5)t(5;13;7), der(5)t(5;13), der(5)t(7;5), 6´3, del(6)(q25), 7´2, der(7)t(7;(8;17)n;14),
8´2, der(?)t(1;17;8;17;8;17;8;1), der(?)t(14;(8;17)n;1), 9´3, 10´3, der(10)t(11;10), 11´1, del(11)(q?)´2, der(11)t(11;10), 12´4, i(13)(q)*, der(?)t(20;14;(8;17)n;14),
der(?)t(14;17;8), der(14)t(20;14), 15´4, 16´4, 17´2, 18´2, 19´4, 20´4, der(21)t(21;13), 22´4, X´4, cp[10]
HB4a 42(35–56) and 69(63–87). 1´1, del(1)(p33), der(2)t(2;3), der(2)t(2;6), der(3)t(3;14)(?;q24.1)´2, der(3)t(2;3), 4´1, 5´2, der(5)t(2;5), 6´2, 7´2, der(7)t(1;7),
8´1, der(8)t(8;13), 9´1, der(9)t(8;9), 10´2, 11´1, der(11)t(4;X?;11), 12´1, der(12)t(9;12)(?;p12.1), 13´2, i(14)(q), der(14)t(14;20), 15´2, 16´1, der(16?)t(16;17),
17´1, der(17)t(17;19), 18´2, 19´1, der(19)t(8;19), 20´2, 21´2, 22´2, X´1, der(?)t(X;9) cp[6]/idem, –i(14), +14, –der(X?)t(X;9), +der(X?)t(5;X;9) [4]/1´2, del(1)´2,
der(2)t(2;3)´2, der(2)t(2;6)´2, der(3)t(3;14)´2, der(3)t(2;3)´2, 4´2, 5´3, der(5)t(2;5), 6´4, 7´4, der(7)t(1;7)´2, 8´3, der(8)t(8;13)´2, 9´1, der(9)t(8;9), 10´2, 11´2,
der(11)t(4;X?;11)´2, 12´1, der(12)t(9;12)´2, 13´4, i(14)´2, der(14)t(14;20)´2, 15´4, 16´2, der(16?)t(16;17)´2, 17´3, der(17)t(17;19), 18´4, 19´2,
der(19)t(8;19)´2, 20´4, 21´4, 22´4, X´2, der(?)t(X;9)´2 [4]
With the exception of CAL51 and MT-3, karyotypes are given as mode (range) then a complete list of chromosomes present. (This is a departure from cytogenetic convention, ISCN 1995,
where chromosome numbers are given as changes from the nearest ploidy, since this can be difficult to interpret with these highly rearranged karyotypes). Chromosomes are listed in the
order that they appear in Figure 1. The copy numbers of each chromosome are the mode, except that all chromosomes present in more than 2/10 metaphases are included and marked
with an asterisk if present in less than half the metaphases. Structural changes are described according to standard (ISCN 1995) nomenclature. Co-amplifications of chromosome
fragments with an unknown number of copies of the co-amplification are indicated as (b;c)n. Translocations were verified by single-dye conventional chromosome painting, except for
some in cell lines VP229 and VP267. Obvious deletions and isochromosomes are noted together with a few breakpoints that were identified as boundaries of CGH changes and
independently by DAPI banding. Clearly distinct clones are indicated in standard nomenclature: they are separated by /, with the number of metaphases examined in square brackets. ‘cp’
indicates that the karyotype given is a composite from a number of slightly differing metaphases. aThe karyotypes of CAL51 and MT-3 were respectively normal diploid and near-diploid, so
are given as deviations from diploid according to ISCN convention, i.e. mode (range), sex chromosome content, numerical and structural changes from diploid. bTranslocations that may
be reciprocal are marked in bold.Chromosome rearrangements in breast cancer 1313
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1997). Briefly, normal genomic DNA and cell line DNA were
labelled with biotin and digoxigenin respectively by DOP-PCR
(Telenius et al, 1992). Cot-1 DNA (GibcoBRL) was added and the
paints hybridized to normal male metaphases (Vysis). The signals
were detected with avidin-TexasRed and FITC-conjugated anti-
digoxigenin antibody. The slides were mounted with Vectashield
(Vector Labs) containing DAPI. At least 15 metaphases were
captured for each cell line on a Zeiss Axioplan II fluorescent
microscope using SmartCapture VP software and analysed by
Quips CGH Karyotyper and Interpreter software (Vysis); or on a
Leica DMRB Microscope, captured using a Kappa CF 8/1 DXC
CCD camera integrating in 256 grey levels, using Starwise soft-
ware from IMSTAR (Paris, France). The threshold set for gains
corresponded to a mean hybridization ratio between tumour and
normal of >1.2:1, and for losses of <0.8:1.
RESULTS AND DISCUSSION
We identified the translocations and numerical changes of the
chromosomes of the 20 cell lines by 24-colour chromosome
painting. As a precaution we confirmed the identity and number of
virtually all the translocations by conventional chromosome
painting, since in certain circumstances the identification provided
by the 24-colour software can be unreliable, as discussed below.
The resulting karyotypes are listed in Table 1. Most are
illustrated in Figure 1, which shows complete or partial representa-
tive metaphases, false-coloured to show the pixel-by-pixel
identification of chromosome material.
Validation of the 24-colour karyotypes
Identifying chromosomes by marking them with combinations of
fluorescence colours works well except where fluorescence from
adjacent chromosome fragments blends to create the colour
mixture of an irrelevant chromosome. This can lead to misidentifi-
cation of complex and small rearrangements, as illustrated in
Figure 1 P, Q. The simplest case is at the breakpoint of a transloca-
tion, where blending of the neighbouring colours suggests the
presence of a thin band of a third chromosome, or even of more
than one other chromosome. Figure 1 P shows a 1;X translocation
in MCF-7. At the junction between the 1 and the X the spectrum
blends to match the spectra of chromosomes 3 and 6. A series of
conventional chromosome painting hybridizations confirmed that
1 and X were indeed present, while 3 and 6 were absent. Most
difficult to identify is where multiple fragments of two or more
chromosomes are interleaved, as commonly occurs in hsrs (cyto-
genetic homogeneously staining regions) in breast carcinomas.
Figure 1 Q shows an example from ZR-75-30 where an hsr
composed of interleaved fragments of chromosome 8 and 17 is
classified as chromosome 4 and, where there is also overlap from
the chromosome 14 fragment, as chromosome 1.
We were able to test whether the final karyotypes were reliable
because we had previously karyotyped completely three of the
lines, MDA-MB-361, T-47D and ZR-75-1, by reverse chromo-
some painting (Morris et al, 1997): the present karyotypes,
obtained without reference to the earlier work, were completely in
agreement, except for two trivial discrepancies: we did not identify
a der(22) reported in ZR-75-1 by Morris et al (1997) nor the very
small marker M20 in T-47D.
Nature of the karyotypes and comparison with primary
material
The carcinoma karyotypes fell into different groups. CAL51 was
perfectly diploid, as previously reported by classical banding
(Gioanni et al, 1990). MT-3 showed minimal deviation from
diploidy – iso13 q, trisomy 7 and loss of X. The iso13q and
trisomy 7 – both readily detected by CGH as the sole abnormalities
– are typical of near-diploid carcinoma karyotypes and CGH
pattern (Dutrillaux, 1995). Two of the lines, MDA-MB-134 and
SK-BR-7, were hypodiploid, showing the net loss of chromosomes
discussed below. Most of the remainder fell in the highly
rearranged, near-triploid range that is typical of a high proportion
of breast cancers. Finally, there were three lines that were some-
what different. SUM-159 and MDA-MB-175 had a relatively
simple karyotype, near diploid but with a slight net gain of chro-
mosomes compared to diploid. MT-1 was unique in being hyper-
tetraploid and the presence of duplicated abnormal chromosomes
strongly suggests that it has endoreduplicated its chromosomes.
This suggests that it may represent the result of endoreduplication
of a slightly hyperdiploid line like SUM-159 or MDA-MB-175.
The range of karyotypes shown by these lines – the number of
rearranged chromosomes as a function of the number of chromo-
somes – was within that of a large series (113) of freshly-isolated
carcinomas surveyed by Dutrillaux et al (1991). However, there
were no lines with highly rearranged karyotypes but fewer than 46
chromosomes, a subset that formed almost 40% of the samples of
Dutrillaux et al. Since such isolates usually also contain endoredu-
plicated (i.e. hypotetraploid) variants, one possible explanation is
that there is more selective pressure in culture than in vivo for
tetraploidization, and such cases yield subtetraploid lines.
CGH
CGH (Figure 2) provides different information from 24-colour
karyotyping, and also can be used to compare the cell lines with
uncultured tumours, since it is equally applicable to cultured cells
and surgical material (e.g. Persson et al, 1999).
CGH complements 24-colour karyotyping in two ways. It
shows deletions and amplification of relatively small regions of
chromosomes, which karyotyping generally misses. But also, it
shows large scale net chromosome copy number changes, which
correlate well with the numerical changes seen by 24-colour
karyotyping, and may be used in favourable cases to identify
which chromosome fragments are present in the unbalanced
translocations (Macville et al, 1999). For example, MaTu has a
mode of 69, so a CGH red:green hybridization ratio of 1.0 corre-
sponds to three copies of a chromosome segment. MaTu has three
apparently normal chromosome 1s and a 3;1 translocation:
CGH gives a ratio of 1.0 for 1p, but around 1.2 for most of 1q,
suggesting that the translocation consists of distal 1q.
Chromosome 4 is present in 2 copies and has a ratio of around 0.8
for all of its length. There are three apparently normal 5s and three
small 5 fragments: the ratio for 5q is 1.0 while 5p is present in
considerable excess, showing that the short 5s are 5p, the size
suggesting iso5p. Thus where the two techniques can be compared,
there is very good agreement, and where CGH shows differences
within a chromosome, this can be used to identify the components
of a translocation, provided the rearrangements are not too
complex, and provided the cell line has one predominant clone.1314 JM Davidson et al
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Figure 2 CGH profiles of breast cell lines and breast cancers. Gains are to the right of each ideogram and losses to the left. Above: Cell lines, (A) CAL51, (B)
HB4a, (C) MaTu, (D) MCF-7, (E) MDA-MB-134, (F) MDA-MB-157, (G) MDA-MB-361, (H) MDA-MB-435, (I) MT-1, (J) MT-3, (K) PMC42, (L) SK-BR-3, (M) SK-
BR-7, (N) SUM-159, (O) T-47D, (P) VP229, (Q) VP267, (R) ZR-75-1, (S) ZR-75-30, (T) MDA-MB-175. Below: 106 fresh cases, described in (Courjal and
Theillet, 1997; Bautista and Theillet, 1998).Figure 2 shows that overall the genetic anomalies in breast
cancer cell lines are good representations of aberrations arising in
uncultured tumours. It compares the CGH profiles for the cell
lines with the gains and losses found in 106 breast tumours
analysed by us (Courjal and Theillet, 1997; Bautista and Theillet,
1998), which are in general agreement with the survey of
Tirkkonen et al (1998). For example, the most frequent gains and
losses seen in the tumours are well represented in the cell lines:
gains of 1q 8q, proximal 11q and 20q, and losses of 8p, distal 11q,
and16q.
Translocations
There was an enormous range of chromosome abnormalities in
these carcinoma lines. All chromosomes were translocated at least
occasionally, and they were translocated to a wide range of
partners. No translocation appears to be present in a substantial
proportion of the lines. The most frequent in the carcinoma lines
were 8;11 in five lines; and 8;17, 1;4 and 1;10 in four lines.
Chromosome 8 was overall the chromosome that was involved
in the most translocations; it was present in a total of 39 distinct
translocated chromosomes in 19 of the cancer cell lines, and was
translocated to all other chromosomes except 5, 10 and 20. Many
of the breakpoints may of course be completely unrelated, but we
have previously shown that some are clustered. The lines MDA-
MB-361, T-47D and ZR-75-1 all have a translocation breaking
within at most 1.5 Mb on 8p12, with loss of distal 8p, as often seen
in carcinomas (Morris et al, 1997; Courtay-Cahen et al, 2000), and
the 8;11 of MDA-MB-175 has a breakpoint within about two to
four megabases of these, within the HGL gene (Wang et al, 1999).
Chromosome 13 also has clustered breaks at 13q12, proximal to
BRCA2, and at 13q14, near to RB-1 (S-F. C. and C.C., unpub-
lished).
Translocations were almost all unbalanced, as expected for
carcinomas (Dutrillaux, 1995). Possible exceptions which might
be reciprocal, merely on the basis of appropriate size pieces and
centromere position where it is known, were the 6;21 in MT-1, the
X;9 of SUM-159, the 2;3 of VP229 and VP267, the 10;11 of ZR-
75–30, and the 2;3 in the normal breast line HB4a. This is not
more than 6 examples out of a total of 341 translocated chromo-
somes, or less than 2%.
Several of the cell lines showed complex multiply-translocated
chromosomes, for example the 6;12;22;15 in MDA-MB-361 and
several in SK-BR-3, MCF-7, VP229, VP267 and ZR-75–30. Many
of these complex rearrangements included a coamplification of
segments of two chromosomes, as commonly occurs in breast
cancers and often gives rise to a cytogenetic hsr (Bautista and
Theillet, 1998; Bernardino et al, 1998). MDA-MB-134 had a
coamplification of 8 and 11 previously described (Bautista and
Theillet, 1998); SK-BR-3 had complex coamplifications of (prin-
cipally) 8, 3 and 13; VP229 and VP267 had several involving
(principally) 3,4,8,10 and 12; ZR-75–30 had alternating 8 and 17.
Not all such coamplifications are likely to be resolved by the 24-
colour chromosome painting – for example we have shown else-
where that the 8;17 translocations of MDA-MB-361 have
alternating fragments of 8 inserted in the chromosome 17 fragment
(Courtay-Cahen et al, 2000). The frequent presence of 8 in
these structures has been noted before (Bernardino et al, 1998;
Courtay-Cahen et al, 2000).
Karyotype patterns and their development
The question of how a karyotype has evolved could be important
because it may reveal the events that lead to translocation or
numerical changes, and the nature of the selective pressures oper-
ating on the resulting gene changes. Dutrillaux and colleagues
(Muleris et al, 1988; Dutrillaux, 1995) described two main modes
of karyotype evolution, designated ‘trisomic’ and ‘monosomic’.
The trisomic type seemed to gain extra chromosomes, while the
monosomic type tended to lose a chromosome when a transloca-
tion occurred. MT-3, with trisomy 7 and iso 13 q is a very simple
trisomic case. MDA-MB-134 is an example of monosomic
pattern: an 8 and an 11 have been replaced by an unbalanced
translocation der(?)t(8;11); a 15 and a 17 have been replaced by a
der(?)t(15;17); and a 16 and an 18 by a der(18)t(16;18). These
have presumably resulted in net losses of one copy (allele) of part
of each chromosome involved. SK-BR-7 presents a similar but
less straightforward case. The great majority of freshly-isolated
breast cancers with diploid or subdiploid karyotypes show the
monosomic pattern of evolution: virtually every case falls between
diploid and a line representing 1 chromosome lost per rearrange-
ment (Dutrillaux et al, 1991). As carcinomas evolve they occasion-
ally reduplicate their entire genome, and sometimes the resulting
cells come to dominate the cancer or cell line. In subsequent evolu-
tion the chromosome number falls further, to produce near-triploid
numbers. It has been suggested that the majority of breast cancers
with near-triploid modes have evolved this way (Dutrillaux et al,
1991).
Our karyotypes suggest however, that near-triploid breast
cancers may fall into two groups which reach a near-triploid chro-
mosome number by two different routes: either by steadily losing
chromosomes and at one point doubling their entire karyotype, or
by steadily gaining chromosomes, together with acquisition of
translocations. The latter may be the same as the ‘trisomic’ pattern
described for near-diploid colon cancers (Muleris et al, 1988;
Dutrillaux, 1995), but progressing to much greater aneuploidy.
The two routes can be distinguished in many cases because the
loss-with-reduplication process leads to a cell with several dupli-
cated abnormal chromosomes, while relentless gain will tend to
generate unique rearranged chromosomes that will only be paired
if an extra copy of the individual abnormal chromosome is
acquired. MDA-MB-157 and T-47D, for example, exactly fit the
loss-with-reduplication prediction, with 9 and 7 duplicated
abnormal chromosomes respectively. MDA-MB-361, on the other
hand, fits the prediction of continuous gain: it has 27 out of 52
of its chromosomes rearranged, yet has no duplicated abnormal
chromosomes, with the exception of two derivatives of a
der(8)t(8;17)(p12;q22–25) (Morris et al, 1997; Courtay-Cahen et
al, 2000). Other examples that clearly fit the continuous gain
pattern are MaTu, MCF-7 and MDA-MB-435. MT-1 may have
endoreduplicated from a line with a few net gains. However, not
all the karyotypes fit these patterns of evolution tidily. MDA-MB-
175, for example, appears to have lost chromosomes in forming
most of its translocations, but at the same time to have gained extra
copies of 20, 21 and 22, and the translocated 8;11.
Are the karyotypes consistent with the published
karyotypes in the literature?
Classical cytogenetic analyses of many of these lines have been
reported in the literature or ATCC catalogue, but, as we and others
Chromosome rearrangements in breast cancer 1315
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have found, FISH results show that interpretation of banding in the
highly aneuploid lines was unreliable, and reconciling FISH and
previous banding results is often difficult (Morris et al, 1997;
Macville et al, 1999). In several of the more complex karyotypes
there were characteristic markers that matched, e.g. the hsr
inserted into chromosome 11 in MDA-MB-134, and paired
markers in T-47D, but in general we can only say that the data are
not incompatible. For MCF-7, the mode of our sample (65, range
61–72) and some markers agree with the authentic MCF-7
samples of Osborne et al (1987). While this paper was in revision,
a parallel molecular cytogenetic study of 15 breast cancer cell
lines, including 7 common to our study, appeared (Kytola et al,
2000). There are significant differences in karyotype between our
samples and theirs of MDA-MB-157, ZR-75-1, and, particularly,
MCF-7. The lines are clearly the same: while it is possible that
some discrepancies were misclassifications by SKY (not all
translocations reported by Kytola et al were verified by conven-
tional chromosome painting), most or all reflect divergence in
culture.
Cell lines that are related to each other: VP229 and
VP267; MaTu and MT-1
VP229 was derived from a primary tumour, taken before any treat-
ment, while VP267 was derived 14 months later from a local
recurrence in the same patient following treatment with
Tamoxifen. As expected, the two karyotypes show a common
ancestral clone, and some similarities in their CGH results, but in
detail they are very different, having evolved independently a
great deal either in vivo or in vitro, so it would not be possible to
associate any differences specifically with progression in vivo.
The karyotypes of MaTu/Ham and MT-1 have at least 6 translo-
cations in common, so they seem to have come from the same
tumour. They were also identical and heterozygous for 4 highly
polymorphic dinucleotide repeats (not shown). We confirmed the
authenticity of our samples by comparing them with second
samples (see Methods).
Comparison of the two lines should show how clones can
evolve, and again suggests that a tumour such as MT-1 that has
a hypertetraploid karyotype, arises by endoreduplication of a
tumour somewhat like MaTu, although sequential gain of chromo-
somes is also a possible explanation.
CONCLUSIONS
The karyotypes we have described update our picture of the range
and nature of translocations found in breast carcinoma cell lines,
which were largely unknown because of their intractability to
banding analysis. Together with the CGH data they add to the
growing evidence (e.g. Wistuba et al, 1998) that the chromosome
abnormalities of breast cancer cell lines are, with minor caveats,
broadly representative of breast cancers, and they provide
a resource for the cataloguing and analysis of translocations
in these tumours. Detailed images can be found at
http://www.path.cam.ac.uk/~pawefish.
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